Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ VPRBP Polyclonal Antibody

Rabbit Polyclonal Antibody

Supplier:  Invitrogen™ PA599967

Catalog No. PIPA599967


Only null left
Add to Cart

Description

Description

Antibody detects endogenous levels of total VPRBP.

Acts both as a substrate recognition component of E3 ubiquitin-protein ligase complexes and as an atypical serine/threonine-protein kinase, playing key roles in various processes such as cell cycle, telomerase regulation and histone modification. Probable substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex, named CUL4A-RBX1-DDB1-DCAF1/VPRBP complex, which mediates ubiquitination and proteasome-dependent degradation of proteins such as NF2. Involved in the turnover of methylated proteins: recognizes and binds methylated proteins via its chromo domain, leading to ubiquitination of target proteins by the RBX1-DDB1-DCAF1/VPRBP complex. The CUL4A-RBX1-DDB1-DCAF1/VPRBP complex is also involved in B-cell development: VPRBP is recruited by RAG1 to ubiquitinate proteins, leading to limit error-prone repair during V(D)J recombination. Also part of the EDVP complex, an E3 ligase complex that mediates ubiquitination of proteins such as TERT, leading to TERT degradation and telomerase inhibition. Also acts as an atypical serine/threonine-protein kinase that specifically mediates phosphorylation of 'Thr-120' of histone H2A (H2AT120ph) in a nucleosomal context, thereby repressing transcription. H2AT120ph is present in the regulatory region of many tumor suppresor genes, down-regulates their transcription and is present at high level in a number of tumors. Involved in JNK-mediated apoptosis during cell competition process via its interaction with LLGL1 and LLGL2. In case of infection by HIV-1 virus, it is recruited by HIV-1 Vpr in order to hijack the CUL4A-RBX1-DDB1-DCAF1/VPRBP function leading to arrest the cell cycle in G2 phase, and also to protect the viral protein from proteasomal degradation by another E3 ubiquitin ligase. The HIV-1 Vpr protein hijacks the CUL4A-RBX1-DDB1-DCAF1/VPRBP complex to promote ubiquitination and degradation of proteins such as TERT and ZIP/ZGPAT. In case of infection by HIV-2 virus, it is recruited by HIV-2 Vpx in order to hijack the CUL4A-RBX1-DDB1-DCAF1/VPRBP function leading to enhanced efficiency of macrophage infection and promotion of the replication of cognate primate lentiviruses in cells of monocyte/macrophage lineage.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

VPRBP
Polyclonal
Unconjugated
DCAF1
AI447437; B930007L02Rik; DCAF1; DDB1 and CUL4 associated factor 1; DDB1- and CUL4-associated factor 1; HIV-1 Vpr binding protein; HIV-1 Vpr-binding protein; KIAA0800; LOW QUALITY PROTEIN: DDB1- and CUL4-associated factor 1; MGC102804; mKIAA0800; Protein VPRBP; protein VPRBP; DDB1- and CUL4-associated factor 1; RGD1305176; RIP; Serine/threonine-protein kinase VPRBP; Vpr (HIV-1) binding protein; Vpr-binding protein; VprBP; vpr-interacting protein
Rabbit
Affinity chromatography
RUO
315987, 321006, 9730
-20°C
Liquid
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry
1 mg/mL
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4
Q80TR8, Q9Y4B6
DCAF1
A synthesized peptide derived from human DCAF1(Accession Q9Y4B6), corresponding to amino acid residues D30-K80.
100 μL
Primary
Human, Mouse, Rat
Antibody
IgG
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.